Abstract
The Paediatric HIV/AIDS, and the subsequent Innovation in Paediatric Market Access (IPMA) projects were both funded by Unitaid and implemented by CHAI. Taken together, the projects aimed to strengthen the paediatric antiretroviral (ARV) market. The main objectives of the evaluation were to assess the public health and market impacts of the two projects, and assess their performance in relation to Unitaid’s strategic objectives of promoting innovation, access and scalability. The evaluation was based on an extensive document review, quantitative data analysis and consultations with key stakeholders, including Unitaid, CHAI, global partners such as WHO, the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and the US President’s Emergency Plan for AIDS Relief (PEPFAR), manufacturers and select country Ministries of Health (MoHs).
